Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Change in Cash (2023 - 2025)

Historic Change in Cash for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $65.1 million.

  • Tonix Pharmaceuticals Holding's Change in Cash rose 17042.53% to $65.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.2 million, marking a year-over-year increase of 66447.52%. This contributed to the annual value of $73.8 million for FY2024, which is 17802.81% up from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported Change in Cash of $65.1 million as of Q3 2025, which was up 17042.53% from -$6.4 million recorded in Q2 2025.
  • Over the past 5 years, Tonix Pharmaceuticals Holding's Change in Cash peaked at $70.5 million during Q4 2024, and registered a low of -$48.3 million during Q1 2023.
  • Its 3-year average for Change in Cash is $6.4 million, with a median of -$2.9 million in 2024.
  • As far as peak fluctuations go, Tonix Pharmaceuticals Holding's Change in Cash skyrocketed by 29338.09% in 2024, and later tumbled by 12063.6% in 2025.
  • Quarter analysis of 3 years shows Tonix Pharmaceuticals Holding's Change in Cash stood at $17.9 million in 2023, then surged by 293.38% to $70.5 million in 2024, then fell by 7.7% to $65.1 million in 2025.
  • Its last three reported values are $65.1 million in Q3 2025, -$6.4 million for Q2 2025, and $32.9 million during Q1 2025.